905 related articles for article (PubMed ID: 19108785)
1. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
Hazarika M; Jiang X; Liu Q; Lee SL; Ramchandani R; Garnett C; Orr MS; Sridhara R; Booth B; Leighton JK; Timmer W; Harapanhalli R; Dagher R; Justice R; Pazdur R
Clin Cancer Res; 2008 Sep; 14(17):5325-31. PubMed ID: 18765523
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
Usuki K; Tojo A; Maeda Y; Kobayashi Y; Matsuda A; Ohyashiki K; Nakaseko C; Kawaguchi T; Tanaka H; Miyamura K; Miyazaki Y; Okamoto S; Oritani K; Okada M; Usui N; Nagai T; Amagasaki T; Wanajo A; Naoe T
Int J Hematol; 2012 Apr; 95(4):409-19. PubMed ID: 22359103
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
6. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
7. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
[TBL] [Abstract][Full Text] [Related]
8. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.
Tojo A; Usuki K; Urabe A; Maeda Y; Kobayashi Y; Jinnai I; Ohyashiki K; Nishimura M; Kawaguchi T; Tanaka H; Miyamura K; Miyazaki Y; Hughes T; Branford S; Okamoto S; Ishikawa J; Okada M; Usui N; Tanii H; Amagasaki T; Natori H; Naoe T
Int J Hematol; 2009 Jun; 89(5):679-88. PubMed ID: 19449194
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
11. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
12. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
Koren-Michowitz M; le Coutre P; Duyster J; Scheid C; Panayiotidis P; Prejzner W; Rowe JM; Schwarz M; Goldschmidt N; Nagler A
Cancer; 2010 Oct; 116(19):4564-72. PubMed ID: 20572041
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
15. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Stein B; Smith BD
Clin Ther; 2010 May; 32(5):804-20. PubMed ID: 20685492
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z
Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Jarkowski A; Sweeney RP
Pharmacotherapy; 2008 Nov; 28(11):1374-82. PubMed ID: 18956997
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
20. [Nilotinib as a second-line treatment for chronic myeloid leukemia].
Yamauchi T; Ueda T
Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]